Alnylam Pharmaceuticals, Inc. continues to make strides in the bio-tech market as evidenced by the variety of events reported recently. The company showcased solid growth with shares being acquired and additional multi-regional partnerships being announced. There is great interest and optimism as Alnylam is now in a unique position to take RNAi from interesting science to impactful new treatments, silencing genes to prevent diseases and thereby potentially outperforming in Q1. Nonetheless, experts highlight a tough path ahead of Alnylam's key ATTR-CM readout, sparking some doubts. Despite the FDA's skepticism, Alnylam seems to have gained expert backing for Onpattro expansion into rare heart disease. Additionally, Alnylam has made successful strides with FDA-approved RNAi treatments. It has been reported that those who invested in Alnylam five years ago have seen a 63% increase on their investment. While a moderate buy recommendation was given by varied brokerages, Alnylam encounters some challenges with FDA rejection of its heart disease treatment citing insufficient data.
Alnylam Pharmaceuticals News Analytics from Sun, 23 Jul 2023 07:00:00 GMT to Sun, 26 May 2024 09:20:06 GMT -
Rating -2
- Innovation 8
- Information 9
- Rumor -3
